The short version of mass spectrometry fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-08-06. Anything still debated is marked as such rather than presented as settled.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
Dry powder is generally stored at low temperature, with minus twenty degrees Celsius or colder advised for extended retention. Reconstituted solutions are less stable than the solid form and are normally kept cold and shielded from repeated freeze-thaw cycles. Light exposure is avoided because some peptides degrade under ultraviolet radiation. The exact rate of degradation depends on concentration, pH, and the presence of salts, so a single shelf life does not apply to every preparation. Reported stability figures should be read as indicative of typical handling rather than as universal constants.
Human data are far more limited than animal data. A small number of clinical reports exist, generally with few participants and without the randomization or blinding expected in later-phase trials. No large, independently replicated human trial has appeared in the indexed peer-reviewed literature. Statements about effects in people therefore rest on extrapolation from animal work rather than on direct evidence, and the strength of that extrapolation remains an open question rather than a settled matter.
Proposed mechanisms include interaction with the nitric oxide system, modulation of growth factor signaling, and effects on blood vessel formation. None of these has been established as the primary mode of action, and some proposed pathways rest on indirect measurements. Whether the reported effects depend on a specific receptor has not been determined. Stability in gastric acid, unusual for a peptide of this size, is also reported in animal work, but the reason for it is not firmly established.
Published studies on BPC-157 are dominated by animal models. Commonly used endpoints include healing of surgically induced lesions in the stomach, tendon-to-bone attachment after transection, and recovery from experimentally induced vascular or intestinal damage. Many of these reports come from a small number of research groups, and the peptide is often described as acting across a wide range of tissue types. That breadth is itself a point of discussion, since one molecule influencing many unrelated systems is unusual.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized powder | Freeze-dried solid, often hygroscopic |
| Solubility class | Freely soluble in water | Aqueous buffers used for stock solutions |
| Storage, dry powder | Minus 20 °C or colder | Recommended for long-term retention |
| Storage, solution | 2–8 °C or frozen | Avoid repeated freeze-thaw cycles |
| Typical analytical method | RP-HPLC with mass spectrometry | Purity percentage plus mass confirmation |
Handling practice centers on limiting moisture, heat, and mechanical stress. Powder is typically allowed to reach room temperature before opening so that condensation does not form on the contents, and solutions are prepared with sterile or low-particulate water. Peptides can adsorb to certain plastics and membrane filters, so container and filter material is sometimes specified to reduce losses at low concentrations. Working aliquots are usually frozen separately rather than sampled repeatedly from one stock. Recording lot number, preparation date, and storage conditions supports later comparison between experiments.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated sequences and other synthesis by-products. Mass spectrometry, typically electrospray ionization coupled to liquid chromatography, confirms the expected mass and helps detect modifications. Amino acid analysis can verify composition when residue-level confirmation is needed. Because common impurities differ from the target by only one or two residues, chromatographic resolution often matters more than a single headline purity percentage. Impurity profiles are most informative when compared against a validated reference standard.
Lyophilized material is generally reported as stable for extended periods when kept cold, dry, and protected from light. In solution, the main degradation routes for a peptide of this type are hydrolysis of peptide bonds and aggregation. The sequence contains no cysteine, so disulfide-driven oxidation is not a primary concern, though methionine and tryptophan are also absent. Stability depends on pH, buffer composition, and concentration, with acidic conditions often reported as more favorable than neutral or alkaline ones. Repeated freeze-thaw cycles can promote aggregation, and how fast degradation proceeds at room temperature in specific formulations remains an open question.
The peptide was first described in the early 1990s by a group studying gastric secretions and tissue repair. Its fifteen-residue chain is usually written as GEPPPGKPADDAGLV in single-letter code. The free peptide has the formula C62H98N16O22 and a theoretical mass near 1419.5 daltons. These identifiers are established chemical facts that can be checked against standard peptide databases. There is no ambiguity about the primary structure.
Most published findings come from rodent experiments using induced injury or surgical models. Human reports remain scarce and are largely observational, which limits how much can be stated with confidence. Questions about absorption, distribution, metabolism, and clearance in people are still open. Dose translation between species is likewise unresolved. Researchers tend to read the animal literature as a starting point rather than a settled account.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
== Safety == In vivo dermal sensitization studies according to OECD 429 confirmed CMDT is a strong skin sensitizer, showing a response at 0.03 wt% in the local lymph node assay (LLNA) placing it in Globally Harmonized System of Classification and Labelling of Chemicals (GHS) Dermal Sensitization Category 1A. These studies confirm that DMTMM is a less sensitizing alternative to CDMT, as suggested by anecdotal observations in the literature.
=== Other uses === Although pregabalin is sometimes prescribed for people with bipolar disorder, there is no evidence that it is effective. There is no evidence and significant risk in using pregabalin for sciatica and low back pain. Evidence of benefit in alcohol withdrawal as well as withdrawal from certain other drugs is limited as of 2016. There is no evidence for its use in the prevention of migraines and gabapentin has also been found not to be useful. A 2025 review found possible benefits to sleep quality in patients with fibromyalgia.
==== Australia ==== In July 2020, remdesivir was provisionally approved for use in Australia for use in adults and adolescents with severe COVID‑19 symptoms who have been hospitalized. Australia claims to have a sufficient supply of remdesivir in its national stockpile.
The pH in the cytoplasm quickly drops when hydrogen ions accumulate in the muscle, eventually inhibiting the enzymes involved in glycolysis. The burning sensation in muscles during hard exercise can be attributed to the release of hydrogen ions during the shift to glucose fermentation from glucose oxidation to carbon dioxide and water, when aerobic metabolism can no longer keep pace with the energy demands of the muscles. These hydrogen ions form a part of lactic acid. The body falls back on this less efficient but faster method of producing ATP under low oxygen conditions. This is thought to have been the primary means of energy production in earlier organisms before oxygen reached high concentrations in the atmosphere between 2000 and 2500 million years ago, and thus would represent a more ancient form of energy production than the aerobic replenishment of NAD+ in cells. The liver in mammals gets rid of this excess lactate by transforming it back into pyruvate under aerobic conditions; see Cori cycle. Fermentation of pyruvate to lactate is sometimes also called "anaerobic glycolysis", however, glycolysis ends with the production of pyruvate regardless of the presence or absence of oxygen. In the above two examples of fermentation, NADH is oxidized by transferring two electrons to pyruvate.
Sources: en.wikipedia.org
== Post-retirement == De retired in 1973 from the Calcutta Medical College at the age of 58. After his retirement, he showed no interest in higher positions but continued his research at the Bose Institute, Calcutta. De's desire to purify the cholera toxin did not progress any further as the protein purification technology was not well established in his research settings. During his time of research, De worked with hypertoxin-producing classical strains of V. cholerae O1, which was abruptly replaced by El Tor biotype [producing less cholera toxin] in Calcutta from 1963. This new development was another reason why De could not continue his research on purification of cholera toxin. In 1978, the Nobel Foundation invited De to participate in the 43rd Nobel Symposium on Cholera and Related Diarrhoeas. De died on 15 April 1985 at the age of 70.
In hemodynamically unstable patients or cardiac arrest, calcium chloride via a large peripheral vein is acceptable when central access is not immediately available. Onset of action is within one to three minutes and lasts approximately 30–60 minutes. The goal of treatment is to normalise the ECG, and doses can be repeated if the ECG does not improve within a few minutes. Some guidelines have historically advised against administering calcium in digoxin toxicity, based on animal models and theoretical concern that elevated intracellular calcium could cause irreversible myocardial contracture (the "stone heart" hypothesis). A retrospective cohort study of 159 patients with digoxin toxicity found no life-threatening dysrhythmias within one hour of intravenous calcium administration, and mortality was similar between those who received calcium and those who did not. The animal models underlying the original concern used serum calcium concentrations substantially higher than those achieved clinically. In confirmed digoxin toxicity, current guidance recommends treating hyperkalemia primarily with digoxin-specific antibody fragments (Fab) when available, with calcium reserved for life-threatening ECG changes if Fab is not immediately accessible.
=== Platelet activation and platelet plug formation === When the endothelium is damaged, the normally isolated underlying collagen is exposed to circulating platelets, which bind directly to collagen with collagen-specific glycoprotein Ia/IIa surface receptors. This adhesion is strengthened further by von Willebrand factor (vWF), which is released from the endothelium and from platelets; vWF forms additional links between the platelets' glycoprotein Ib/IX/V and A1 domain. This localization of platelets to the extracellular matrix promotes collagen interaction with platelet glycoprotein VI. Binding of collagen to glycoprotein VI triggers a signaling cascade that results in activation of platelet integrins. Activated integrins mediate tight binding of platelets to the extracellular matrix. This process adheres platelets to the site of injury. Activated platelets release the contents of stored granules into the blood plasma. The granules include ADP, serotonin, platelet-activating factor (PAF), vWF, platelet factor 4, and thromboxane A2 (TXA2), which, in turn, activate additional platelets. The granules' contents activate a Gq-linked protein receptor cascade, resulting in increased calcium concentration in the platelets' cytosol. The calcium activates protein kinase C, which, in turn, activates phospholipase A2 (PLA2). PLA2 then modifies the integrin membrane glycoprotein IIb/IIIa, increasing its affinity to bind fibrinogen.
=== Soft nanoparticles === Most soft nanoparticles have core–shell structures. The semiflexible surface ligands soften the interaction of the cores and create a more spherical shape than the underlying core from uniform coverage. The surface ligands can be chosen from surfactants, polymers, DNA, ions, etc. Tuning the structure of superlattices can be achieved by varying the amount of surface ligands. Their "soft" behavior results in different self-assembly rules from hard particles, where Pauling's rules expired. To tailor the superlattice structure of soft nanoparticles, six design rules of spherical nanoparticle superlattice are established based on the study of metal–DNA nanoparticles:
Sorenson, MD, from the Mayo Clinic in Rochester, Minnesota "While this is very disappointing, at least it was definitive and gives, I think, a pretty definitive answer, at least for this strategy for this drug," Dr. Sorenson said. However, he added, "there is still a great deal of evidence that the IGF-1 pathway can be beneficial to people who have ALS, but just not the way we administered it." Novel methods of delivering IGF-1 in a more selected fashion are now under way, including the use of viral mediators or stem cells. Two previous phase 3 trials of IGF-1 in ALS showed inconsistent results: 1 trial, carried out in North America, did find a benefit, whereas the other, a European trial, did not confirm the earlier findings. "The results of our study most resemble those of the previous European study, with no benefit in either survival or functional scales", De Sorenson concludes. "It is disappointing that we were unable to confirm the benefit that was noted in the previous North American study." Conclusive evidence points, what Iplex (and any form of IGF-1) can't slow progression in human ALS. Lot of sites that have published articles about the link between Lyme disease and ALS are sponsored by clinics specializing in the treatment of chronic Lyme disease, or by the sellers of products for treating this, or both.
Sources: en.wikipedia.org
The lyophilized powder is normally kept at minus twenty degrees Celsius or colder. Solutions are held at refrigerator temperature or below and protected from light. Repeated freezing and thawing is avoided because it can promote aggregation or loss of activity.
Reverse-phase liquid chromatography is used to assess purity, and mass spectrometry confirms molecular mass. Together these two checks form the most widespread approach. Some laboratories add amino acid analysis for further verification.
Yes. The peptide is freely soluble in water and in aqueous buffers, so reconstitution does not require an organic solvent. Stock solutions are usually prepared in water or a mild buffer. Exact handling depends on the intended downstream application.
It is not authorized as a medicine in the United States or the European Union. Regulatory treatment varies by jurisdiction, and in several places it is handled as a research chemical. Therapeutic claims are not supported by large human trials.